635 related articles for article (PubMed ID: 23870164)
1. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
6. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
J Clin Microbiol; 2007 Mar; 45(3):796-802. PubMed ID: 17215344
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the VITEK 2 system (AST-YSO1 cards) for antifungal susceptibility testing against different Candida species].
Ochiuzzi ME; Arechavala A; Guelfand L; Maldonado I; Soloaga R;
Rev Argent Microbiol; 2014; 46(2):111-8. PubMed ID: 25011594
[TBL] [Abstract][Full Text] [Related]
9. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199
[TBL] [Abstract][Full Text] [Related]
10. Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.
Pfaller MA; Diekema DJ; Procop GW; Wiederhold NP
J Clin Microbiol; 2014 Jun; 52(6):2126-30. PubMed ID: 24719450
[TBL] [Abstract][Full Text] [Related]
11. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
13. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Pfaller MA; Bustamante B; Canton E; Fothergill A; Fuller J; Gonzalez GM; Lass-Flörl C; Lockhart SR; Martin-Mazuelos E; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Szeszs MW; St-Germain G; Bonfietti LX; Guarro J; Turnidge J
Antimicrob Agents Chemother; 2014; 58(4):2006-12. PubMed ID: 24419346
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Six Antifungal Susceptibilities of 11
Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
[TBL] [Abstract][Full Text] [Related]
15. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
[TBL] [Abstract][Full Text] [Related]
16. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
[TBL] [Abstract][Full Text] [Related]
17. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
18. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
19. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.
Kronvall G; Karlsson I
J Clin Microbiol; 2001 Apr; 39(4):1422-8. PubMed ID: 11283066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
